AKT1 and neoplasm: Indeed, targeting AKT signaling by siRNA also significantly inhibited tumor cell growth, migration and invasion, suggesting that AKT is the downstream of SPLI and may be a promising therapeutic target in colorectal cancer with high SLPI expression.